Malin Corporation plc

MLC · IR · Healthcare / Drug Manufacturers - Specialty & Generic

6.00EUR+0.05 (+0.84%)

Price History

Full chart

Market Stats

Previous Close5.95

Open6.00

Day Range6.00 – 6.00

52-Week Range5.95 – 9.30

Volume10

Market Cap25.74M

P/E (TTM)0.00

Forward P/E0.00

EPS0.00

Dividend Yield0.00%

Beta0.47

50-Day Avg6.81

200-Day Avg7.36

About

Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. William F. Daniel
Employees2
HeadquartersThe Lennox Building, Dublin, Ireland, D02 FK02, Ireland
Websitehttps://malinplc.com

Leadership

Mr. William F. DanielExecutive Chair · b. 1952
Andrea StaffordHead of Finance & Company Secretary

Financials

Income Statement

Currency: EUR	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31
Total Revenue	22.90M	42.10M	41.90M	38.00M	34.90M	41.00M	0	0	0	0
Growth (%)	-	+83.84%	-0.48%	-9.31%	-8.16%	+17.48%	-100.00%	-	-	-
Cost of Revenue	19.30M	30.60M	30.80M	33.90M	27.40M	30.80M	-	-	-	-
Gross Profit	3.60M	11.50M	11.10M	4.10M	7.50M	10.20M	-	-	-	-
Gross Margin	15.72%	27.32%	26.49%	10.79%	21.49%	24.88%	-	-	-	-
Operating Expense	30.60M	58.00M	56.40M	27.40M	21.50M	19.10M	-	-	-	-
Operating Income	-27.00M	-46.50M	-45.30M	-23.30M	-14.00M	-8.90M	-2.60M	-700.00K	-3.90M	-2.50M
Operating Margin	-117.90%	-110.45%	-108.11%	-61.32%	-40.11%	-21.71%	-	-	-	-
EBITDA	-41.70M	-76.20M	-91.60M	-39.10M	1.70M	100.20M	2.70M	12.80M	400.00K	300.00K
EBITDA Margin	-182.10%	-181.00%	-218.62%	-102.89%	4.87%	244.39%	-	-	-	-
Net Income	-44.90M	-83.50M	-98.80M	-46.30M	-5.40M	87.70M	37.80M	12.90M	0	0
Net Income Margin	-196.07%	-198.34%	-235.80%	-121.84%	-15.47%	213.90%	-	-	-	-
R&D	2.70M	5.10M	11.50M	3.90M	2.70M	6.60M	-	-	-	-
R&D as % of Total Revenue	11.79%	12.11%	27.45%	10.26%	7.74%	16.10%	-	-	-	-
Interest Expense	800.00K	2.00M	3.00M	2.90M	3.30M	3.40M	1.20M	200.00K	200.00K	200.00K
Interest Expense % of Total Revenue	3.49%	4.75%	7.16%	7.63%	9.46%	8.29%	-	-	-	-

Balance Sheet

Currency: EUR	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31
Total Assets	424.20M	402.90M	308.00M	264.40M	271.80M	370.60M	228.20M	287.90M	116.60M	198.50M
Total Liabilities	58.80M	94.80M	86.60M	94.00M	92.70M	80.50M	9.30M	4.80M	7.10M	5.30M
Total Equity	349.30M	286.00M	207.30M	160.50M	168.90M	279.80M	218.90M	283.10M	109.50M	193.20M
Cash	97.00M	46.90M	27.10M	47.90M	28.20M	15.90M	32.70M	173.90M	29.30M	62.10M
Total Debt	34.90M	67.60M	63.50M	73.00M	69.60M	56.40M	100.00K	-	-	-
Net Debt	-62.10M	20.70M	36.40M	25.10M	41.40M	40.50M	-32.60M	-	-	-

Cash Flow

Currency: EUR	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31
Operating Cash Flow	-17.00M	-22.40M	-27.20M	-13.40M	-4.10M	-3.00M	-4.60M	-7.20M	-3.20M	-1.30M
Investing Cash Flow	-229.85M	-58.10M	-16.30M	-2.10M	-6.30M	4.10M	165.50M	-	-	-
Financing Cash Flow	363.00M	32.20M	22.70M	36.90M	-4.70M	-13.50M	-143.60M	-	-	-
Capital Expenditure	800.00K	3.10M	4.20M	4.90M	2.80M	2.10M	1.60M	0	0	0
Free Cash Flow	-17.80M	-25.50M	-31.40M	-18.30M	-6.90M	-5.10M	-6.20M	-7.20M	-3.20M	-1.30M
FCF to OCF	104.71%	113.84%	115.44%	136.57%	168.29%	170.00%	134.78%	100.00%	100.00%	100.00%

Key Statistics & Ratios

Market Cap25.74M

Enterprise Value-36.36M

Trailing P/E0.00

Forward P/E0.00

Price / Sales6.18

Price / Book0.13

EPS0.00

Book Value8.90

Revenue (TTM)41.00M

Gross Profit (TTM)10.20M

EBITDA-2.40M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-5.95%

Return on Assets-1.40%

Shares Outstanding4.33M

Shares Float892.64K

Beta0.47

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%